Faculty Bios top

Dara L. Aisner, MD, PhD
Assistant Professor
Department of Pathology
Co-Director of the Colorado Molecular Correlates Laboratory
University of Colorado School of Medicine
University of Colorado Cancer Center
Denver, CO

Dara L. Aisner, MD, PhD top

Dr. Dara Aisner is a board-certified certified pathologist and is currently eligible for board certification in Molecular Genetic Pathology. She is an Assistant Professor at the University of Colorado School of Medicine in Denver, Colorado and a member of the University of Colorado Comprehensive Cancer Center. She has held this position since 2010.

She is a member of numerous oncology pathology and guidelines committees including the College of American Pathologists (CAP), Association for Molecular Pathology, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer, among many others. She is a member of the United States and Canadian Academy ies of Pathology Dr. Aisner is a leader among her academic peers in helping establish formal processes helping medical oncologists and pathologists work optimally together, which is especially important in today’s world of companion diagnostics, personalized medicine and Next-generation sequencing testing.

Dr. Aisner is the recipient of numerous awards, special recognitions and honors including:

  • CAP Foundation Research Grant, 2009-2010; Project Title: Identification and Validation of Gene Targets for CpG Promoter Methylation for Risk Stratification in GIST
  • REACH Resident Research Award Grant, 2009-2010; Project Title: MicroRNA Expression in H.pylori associated Gastric Carcinogenesis
  • H.T. Enterline Surgical Pathology Fellowship Award; University of Pennsylvania; June 2009
  • Merck Scholars Training Grant, University of Texas Southwestern Medical School Medical Scientist Training Program
  • Magna cum Laude; Vanderbilt University; June 1996
  • Phi Beta Kappa; Vanderbilt University; March 1996

Dr. Aisner’s academic education background is as follows

  • 7/2009 – 6/2010 | Fellow, Molecular and Genetic Pathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania Hospital - Philadelphia, Pennsylvania
  • 7/2008 - 6/2009 | Fellow, Surgical Pathology Department of Pathology and Laboratory Medicine, University of Pennsylvania Hospital - Philadelphia, Pennsylvania
  • 7/2007 - 6/2008 | Resident/Clinical Fellow, Anatomic Pathology; National Institutes of Health, & 7/2004 - 9/2006 Bethesda, Maryland
  • 5/1996 - 6/2004 | MD; University of Texas Southwestern Medical School at Dallas - Dallas, Texas
  • 5/1996 - 6/2004 | PhD; University of Texas Southwestern Graduate School - Dallas, Texas
  • 8/1992 - 6/1996 | BS, Magna Cum Laude, Molecular Biology with honors; Vanderbilt University - Nashville, Tennessee

Dr. Aisner is the author of numerous publications and book chapters.

Hossein Borghaei, DO
Chief, Division of Thoracic Medical Oncology
Director, Lung Cancer Risk Assessment
Associate Professor
Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

Hossein Borghaei, DOtop

Director of Thoracic Medical Oncology and Co-Leader of Thoracic Cancer Service at Fox Chase Cancer Center. Hossein Borghaei serves as the Chief of Thoracic Medical Oncology and Director of the Lung Cancer Risk Assessment Program at Fox Chase Cancer Center. Hossein Borghaei has been Member of Scientific Advisory Board at Oncobiologics, Inc., since May 2012. Dr. Borghaei completed his oncology/hematology fellowship at the Fox Chase Cancer Center and decided that the Fox Chase philosophy and environment provides his patients with an environment that is not only patient friendly but also a place where excellent cancer care can be delivered. Dr. Boghaei can offer many of the top clinical trials in lung cancer to his patients if they need an investigational anti-cancer agent and which also helps advance the field of lung cancer therapy.

Paul A. Bunn, Jr., MD
Distinguished Professor
Division of Medical Oncology
University of Colorado Denver
James Dudley Chair in Lung Cancer Research
Denver, CO

Paul A. Bunn, Jr., MD top

Dr. Paul Bunn is arguably one of the most important lung cancer medical oncologist researchers today and among the few experts during the past several decades.

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center.

Dr. Bunn has also been President of the American Society of Clinical Oncology the leading cancer organization of oncology professionals in the world. The network of the American Society of Clinical Oncology comprises nearly 40,000 oncology professionals, about one-third being from more than 100 countries outside of the USA. This organization is dedicated to providing the highest-quality resources in education, policy, clinical research, and in advancing care for patients with cancer. The results of clinical trials presented at its annual meeting are a benchmark of year-to-year progress in the fight against cancer. ASCO’s flagship publication, the Journal of Clinical Oncology (JCO), is an authoritative resource for cancer research findings.

Dr. Bunn has also been the President and Executive Director of the International Association for the Study of Lung Cancer (IASLC) where he held both positions for almost 20 years, until 2013. Under his leadership Dr. Bunn built the IASLC to become the world’s largest association of oncologists, pathologists and healthcare professionals in lung cancer.

Dr. Bunn has also been the President of the Association of American Cancer Institutes (AACI) and has served on the prestigious FDA Oncology Drug Advisory Committee (ODAC) as its chairman.

He is the Chair or Co-Chair of numerous ongoing educational symposia and scientific, clinical and translational research meetings in lung cancer, including the Annual Targeted Therapies for Lung Cancer Meeting now in its seventeenth year held annually in Santa Monica, CA, the Annual Personalized Therapies and Best Clinical Practices for Lung Cancer now in its 9th year, held each year in October in San Francisco, and many others.

Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, over 122 reviews and editorials, and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research in lung cancer.

Walter J. Curran, Jr.,MD
Executive Director, Winship Cancer Institute
Associate Vice President, Cancer,
Woodruff Health Sciences Center
Lawrence W. Davis Professor and Chairman of Radiation Oncology
Group Chairman and Principal Investigator, NRG
Atlanta, GA

Walter J. Curran, Jr.,MD top

Walter J. Curran was appointed Executive Director of the Winship Cancer Institute of Emory University in September 2009. He joined Emory in January 2008, as the Lawrence W. Davis Professor and Chair of Radiation Oncology and Chief Medical Officer of the Winship Cancer Institute.

Prior to joining Emory, Dr. Curran was Chairman of Radiation Oncology at Thomas Jefferson University. He currently serves as Group Chairman and Principal Investigator of the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-funded cooperative group, a position he has held since 1997.

Dr. Curran, who is a Georgia Cancer Coalition Distinguished Cancer Scholar, has been a principal investigator on several National Cancer Institute (NCI) grants and is considered an international expert in the management of patients with locally advanced lung cancer and malignant brain tumors. He has led several landmark clinical and translational trials in both areas and is responsible for defining a universally adopted staging system for patients with malignant glioma. He has authored or co-authored more than four hundred abstracts and scholarly papers, as well as numerous presentations, reviews and book chapters.

He has been chairman or co-chairman of more than 40 clinical trials and a reviewer for twelve national/international journals. He serves as the Founding Secretary/Treasurer of the Coalition of Cancer Cooperative Groups and a Board Member of the Georgia Center for Oncology Research and Education (Ga CORE). Dr. Curran is the only individual currently serving as director of an NCI-designated cancer center and as group chairman of an NCI-supported cancer cooperative group.

Dr. Curran is a Fellow in the American College of Radiology and has been awarded honorary memberships in the European Society of Therapeutic Radiology and Oncology and the Canadian Association of Radiation Oncology. In 2006, he was named the leading radiation oncologist/cancer researcher in a peer survey by the journal Medical Imaging. Under Dr. Curran’s leadership Emory’s Radiation Oncology Department has been recently selected as a “Top Five Radiation Therapy Centers to Watch in 2009” by Imaging Technology News. Dr. Curran ranked among the top 10 principal investigators in terms of overall NCI funding in 2010 and among the top 20 principal investigators in overall NIH funding in 2010.

Dr. Curran graduated cum laude from Dartmouth College, received his MD degree from the Medical College of Georgia, and is a Board Certified Radiation Oncologist. He completed his residency in the Department of Radiation Therapy at the University of Pennsylvania Medical Center and his internship in internal medicine at Presbyterian University of Pennsylvania Medical Center in Philadelphia.

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Assistant Professor of Nursing
Division of Acute Care/Health Systems
Thoracic Oncology Program
Yale School of Nursing
Yale Cancer Center
New Haven, CT

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP top

Dr. Marianne Davies is Assistant Professor of Nursing at Yale University School of Nursing.

She re-joined Yale University with multiple years of graduate teaching experience at Yale University School of Nursing, and has been involved at Yale-New Haven Hospital’s Cancer Center since 1983. In the past, Marianne Davies has worked as an advanced oncology certified nurse. She is currently an acute care nurse practitioner, advanced oncology certified nurse practitioner and clinical nurse specialist in adult health.

She began her nursing education at Russell Sage College in 1983. She continued her education in New Haven, Conn., and received both her Masters and Post Master’s Certificate at YSN. Marianne Davies then pursued a Doctorate of Nursing Practice at the MGH Institute of Health Profession in Boston, Mass.

In addition to teaching, Marianne Davies has received various awards and honors. She is the recipient of Cogswell Award, Outstanding Student Leadership and Community Involvement, Yale-New Haven Hospital Medical Staff Patient Experience Recognition, the Ruth McCorkle Oncology Advanced Practice Provider: Yale Cancer Center and Nightingale Award for Excellence in Nursing.

Marianne Davies also belongs to Sigma Theta Tau, the National Honor Society of Nursing, the Connecticut Nurse Practitioner Association, the Oncology Nursing Society and the International Association for the Study of Lung Cancer.

Dr. Davies is the author of numerous publications and book chapters involving oncology nursing and is considered among the top oncology nurses in the USA by her peers. She is actively involved in teaching, clinical research and also in cancer education for nurses and other oncology HealthCare Professionals. Dr. Davies is actively involved in numerous ongoing live and Web-based educational symposia including the annual Personalized Therapies and best Clinical Practices for Lung Cancer Symposium, now in its 9th year. She is also actively involved with annual Oncology Nursing Society and Advanced Nurse Practitioner educational activities.

Dr. Davies is the author of numerous publications and book chapters regarding oncology and cancer nursing.

Shirish M. Gadgeel, MD
Director of the Thoracic Oncology program
Karmanos Cancer Center
Wayne State University
Detroit, MI

Shirish M. Gadgeel, MDtop

After completing the first portion of his medical training in India, Shirish Gadgeel, M.D., moved to America to study internal medicine at LaGuardia Hospital in New York. He had already spent three years studying internal medicine at the University of Bombay, but continued his studies in internal medicine as well as further specialization in hematology/oncology and bone marrow transplantation in the United States.

The year before beginning his internship at LaGuardia Hospital, Dr. Gadgeel had served as a Department of Internal Medicine staff physician at the University of Bombay. He chose to further his education for the next six years before obtaining licensure from the Michigan Board of Medicine and returning his attention to his clinical practice.

As the medical oncology team leader at the Barbara Karmanos Cancer Institute’s Multidisciplinary Thoracic Oncology Team, Dr. Gadgeel is one of the center’s foremost experts in mesothelioma and lung cancer care. The team hosts a collaborative meeting each Thursday, where specialists from a number of distinct disciplines strive to create a thorough therapy plan for each patient. When possible, Gadgeel and his team incorporate the most promising combination of surgery, chemotherapy, radiation therapy and other services.

When taking his board certification exams, Dr. Gadgeel scored in the top 10 percentile for the hematology, medical oncology and internal medicine tests. Since earning his certifications, he has served as a reviewer for a number of scholarly journals, including Clinical Lung Cancer, Expert Review of Anticancer Therapy and the Annals of Surgical Oncology.

Dr. Gadgeel has contributed to several major mesothelioma research projects, including a study with renowned mesothelioma specialist, Harvey Pass, M.D. The colleagues published a case history of a male pleural mesothelioma patient whose lung capacity had been reduced to only 77 percent of its expected function. Gadgeel and Pass explained the treatment choices selected for the patient as well as the outcomes, which ultimately halted the patient’s tumor progression.

Dr. Gadgeel’s team at the Karmanos Cancer Center takes a special interest in developing new screening and detection tests for mesothelioma. In fall 2011 they operated two mesothelioma-specific clinical trials, including a study of novel mesothelioma therapeutics and a phase 2 study of pemetrexed and cisplatin.

Several of Dr. Gadgeel’s research projects have been selected for presentation at major scholastic and academic conventions, such as the 2nd Annual Gianni Ferraroti Lung Cancer Foundation convention. Gadgeel was also interviewed for a news item on lung cancer by a local programming channel.

Dr. Gadgeel has contributed to nearly 50 articles, many of which discuss genetic factors of cancer treatment. He has also authored the reviews of several clinical trials, including a 2011 phase 2 study of pemetrexed and cisplatin for lung cancer patients, as well as another 2011 phase 2 trial for platinum-based chemotherapy with maintenance therapy.

Edward B. Garon, MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Edward B. Garon, MDtop

Dr. Garon received his MD degree from the Washington University School of Medicine in 1999, and his internal medicine training at the University of Chicago. He trained in Medical Oncology at UCLA, and joined the UCLA faculty in 2006. In 2008 he was appointed as an Assistant Professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/ Oncology. Dr. Garon has been awarded a UCLA Lung SPORE Career Development Award in 2007, the Tower Cancer Research Foundation Career Development Award in 2008, a Lincy Foundation Grant in 2008, a NIH/NCI K23 award in 2011, a JCCC Seed Grant in 2012, and a STOP CANCER Norman Gilfenbain Memorial Seed Grant in 2014.

Degrees:
M.D., Washington University School of Medicine, 1995 - 1999

Fellowship:
2003 - 2006 UCLA School of Medicine

Internship:
1999 - 2000 University of Chicago Hospitals

Residency:
2000 - 2002 University of Chicago Hospitals

Certifications:
2006 American Board of Internal Medicine
2002 American Board of Internal Medicine

Richard Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, NY

Richard Gralla, MD, FACP top

Dr. Richard J. Gralla, M.D. serves as the President of the New York Lung Cancer Alliance in New York. Dr. Gralla serves as the Chief of Thoracic Oncology at Memorial Sloan-Kettering Cancer Center (New York). He serves as the Vice President for cancer services and Chief of Hematology and Oncology at the Monter Cancer Center of the North Shore - Long Island Jewish Health System, Inc. in Lake Success, New York.

He has over 30 years of experience in cancer care and has held positions at Ochsner Cancer Institute in New Orleans, Louisiana. He served as the President of the Multinational Association of Supportive Care in Cancer (MASCC). He has been a Member of Solid Tumor Advisory Board at Ambit Biosciences Corporation since February 28, 2008. Dr. Gralla serves as a Member of the Scientific Advisory Board at Adventrx Pharmaceuticals Inc. He serves as Member of Scientific Advisory Board of Mast Therapeutics, Inc. Dr. Gralla serves as a Director of the Ochsner Cancer Institute in New Orleans, Louisiana.

He served as a Professor of medicine, Columbia University. Dr. Gralla is the author of over 200 scientific publications in cancer medicine. He also serves on several editorial boards of medical journals and is active in numerous professional societies, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer; he is past president of the Multinational Association for Supportive Care in Cancer. He completed a fellowship in medical oncology and was a National Cancer Institute fellow in clinical research at Memorial Sloan-Kettering Cancer Center. Dr. Gralla received his medical degree from the University of Virginia, Charlottesville, VA, and a bachelor's degree from Brown University in Providence, RI.

Fred Hirsch, MD, PhD
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair
Associate Director, University of Colorado Cancer Center
CEO, International Association for the Study of Lung Cancer (IASLC)
Denver, CO

Fred Hirsch, MD, PhDtop

Research

Dr. Hirsch has worked with clinical/ translational research in lung cancer for more than 25 years. His current interest is in biomarker developments for early detection, chemoprevention and treatment of lung cancer. He is also studying markers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment.

The biomarker studies relate to the development of molecular targeted therapies for chemoprevention and treatment of lung cancer including studies on lung cancer cell lines and tumor tissue from clinical cohorts. Within the last years focus has been on identifying biomarkers, which can be used to select lung cancer patients to EGFR tyrosine kinase inhibitors and other EGFR inhibitors. Dr. Hirsch’s laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe both in lung and head and neck cancer.

Publications

Hirsch FR, Varella-Garcia M, Bunn PA et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol,24: 5034-5042. 2006.

Hirsch FR, McCoy J, West H et al: Increased EGFR gene copy number detected by FISH associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes. J Clin Oncol 23:6838-6845, 2005.

Hirsch FR and Lippman S. Advances in the biology of lung cancer prevention. J Clin Oncol 23: 3186-97, 2005.

Cappuzzo F, Hirsch FR, Rossi E. Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Jr., Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity non-small cell lung cancer. J Natl Cancer Inst. 97, 643-55, 2005.

Funding

Dr. Hirsch is participating in several NIH grants, and is Co-PI for one of the projects ion the Lung SPORE program as well as co-PI for the multi-institutional SPECS grant (molecular signatures of lung cancer). He is also PI for several pharmaceutical research contracts.

Jim Koeller, MS
Professor
University of Texas at Austin
College of Pharmacy
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine
Pharmacotherapy Education & Research Center
San Antonio, TX

Jim Koeller, MS top

Jim M. Koeller serves as a Clinical Professor of Medicine and Pharmacology at the University of Texas Health Science Center in San Antonio. Prior to his arrival in Texas, Professor Koeller was responsible for coordinating the Phase I Drug Development Program in the Department of Human Oncology, Wisconsin Comprehensive Cancer Center in Madison, Wisconsin.

Jim Koeller is a member of the Center for Pharmacoeconomic Studies in the College of Pharmacy at the University of Texas at Austin. He has published over 250 articles, abstracts, and book chapters with a focus on oncology practice, pharmacoeconomics, new drug development, and supportive care issues of the cancer patient. Additionally, he has given over 500 presentations related to oncology, supportive care, pharmacoeconomics, cancer disease management and health care economics.

Professor Koeller received his undergraduate and graduate degrees from the University of Wisconsin-Madison, and completed a residency at the University of Wisconsin Hospital. He holds the Eli Lilly/CR Sublett Endowed Fellowship in Pharmacy.

Professor Koeller is actively engaged in the research and publication of numerous areas of pharmacoeconomic research with oncology/hematology and supportive care cancer therapies. He is currently very actively involved with innovative models and potential new policies for improving the reimbursement of cancer healthcare by utilizing the value-based approach versus the traditional fee-for-service based system for cancer therapy payment and reimbursement.

Jim is the author of numerous cancer publications for both pharmacists and oncologists and is considered one of the best academic thought leaders in oncology/hematology economics. He is actively involved with ongoing pharmacy and oncologist education thorough various organizations including HOPA (Hematology-Oncology Pharmacy Association) as well as with other annual educational programs including the annual Personalized Therapies and Best Clinical Practices for Lung Cancer Symposium, and most recently the forthcoming 1st Annual Symposium on Integrating immune Therapy and Targeted Therapy Into Standards of Care for Hematologic and Solid Malignancies, September 10, 2016 in San Francisco.

Stephen G. Madison, BSc.Pharm, RPh, MBA, CHCP
President and CEO
Oncology Learning Center, Inc., and the
BioMedical Learning Institute
Plano, TX

Owner of InsiderMD, CPLS, Steve Madison Cancer Consulting, Oncology Insights, and Cancer Comm®
Dallas, TX

Stephen G. Madison, BSc.Pharm, RPh, MBA, CHCP top

Steve Madison has been involved with the science and business of oncology/hematology since 1983. He started his career in the field of oncology and hematology as an oncology pharmacist, employed as a pharmaceutical industry marketing executive of Bristol-Myers (BM) for the BM oncology products starting in 1983 as one of only two international marketing executives within BM. In 1983, there were only three cancer pharmaceutical companies in the USA: Bristol-Myers (BM), Mead Johnson and Adria Laboratories. Steve was fortunate to have started establishing working relationships with the academic (“KOL”) leaders in oncology and hematology at the beginning of the oncology business era, 36 years ago. And to this day in 2016, Steve has maintained his important KOL relationships beginning with his employment at Bristol-Myers, but also through his subsequent cancer education and medical advertising companies as described below.

In 1994 Steve left Bristol-Myers and founded and operated, SG Madison & Associates, a global medical/marketing communications and advertising company, which as agency of record, helped successfully launch gemcitabine, trastuzumab, rituximab, cetuximab, and several other oncology and HIV products; but primarily Steve and his medical/marketing company supported the oncology & HIV franchises of Bristol-Myers (eventually Bristol-Myers Squibb) in the US and Globally, plus the businesses of ImClone, Genentech, Lilly and several other companies not on a retainer basis.

In 1999 Steve founded the first of his two CME/CE accredited companies: the CBCE (Center for Biomedical Continuing Education) which he sold in 2001 along with his medical/marketing communications agency, SG Madison & Associates. During his tenure at his two CME/CE companies and SG Madison & Associates, Steve founded several major ongoing cancer education meetings and symposia, and at least two of which are still ongoing today, including the now 17th Annual Anti-Angiogenic Symposium held each year in La Jolla, CA, sponsored by MD Anderson Cancer Center and co-chaired by Dr. George Sledge and Lee Ellis, the now 17th Annual Targeted Therapies for Lung Cancer Meeting, held each year in Santa Monica, CA, sponsored by the IASLC co-chaired by Drs. Paul Bunn, Roy Herbst, Dave Johnson and Fred Hirsch.

In 2006 Steve founded the Oncology Learning Center, Inc., (also operated as the BioMedical Learning Institute) which conducts numerous live and Web-based oncology/hematology educational CME/CE activities, including annual satellite CME/CE symposia at the annual meetings of the American Society of Clinical Oncology, the American Society of Hematology, the San Antonio Breast Cancer Symposium, the Oncology Nursing Society and many other meetings and congresses, and including of its own, stand-alone educational events (of the BLMI) including the annual Symposium on Personalized Therapies and Best Clinical Practices for lung Cancer now in its 9th consecutive year, and its 1st Annual Symposium on Integrating Immune Therapy and Targeted Therapy into Standards of Care for Hematologic and Solid Malignancies to be held on September 10, 2016 in San Francisco.

In addition, Steve and the Oncology Learning Center have now resumed the highly successful Cancer Master Classes that were suspended in 2005, beginning with the October 19-21, 2016 Strategic Cancer Business Master Class and Other Master Classes will follow shortly. Please see: www.OncologyLearningCenter.com

Finally, Steve owns but does not (presently) operate several other cancer businesses of importance to pharmaceutical and diagnostic/laboratory companies, including his cancer consulting company, Steve Madison Cancer Consulting, as well as his oncology KOL development company: InsiderMD.com; his customized oncology training company: CPLS.com (Customized Pharmaceutical Learning Systems), and also his customized cancer market research company: Oncology Insights.com. The reason for Steve’s lack of involvement (for the present), is the 2009 legislation prohibiting his participation in both CME and non CME companies. It is anticipated that this will change in the very near future as Steve his other executives to operate his CME business, thus enabling Steve to operate freely inside his non-CME businesses: InsiderMD.com, CPLS.com (Customized Pharmaceutical Learning Systems), Steve Madison Consulting.com and Oncology Insights.com. Should anyone be interested in any of these business or their services please contact Steve.Madison@CPLS.com.

Ronald B. Natale, MD
Director
Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Ronald B. Natale, MD top

Dr. Ronald B. Natale is the director of the Lung Cancer Clinical Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center in Los Angeles. Dr. Natale is internationally renowned for his clinical research in lung and genitourinary cancers. He has published more than 250 articles and abstracts, authored chapters on lung cancer in several books and presented results of his research at cancer research meetings all over the world. Dr. Natale has developed or co-developed some the most widely used chemotherapy regimens in the world for small cell and non-small cell lung cancers (such as cisplatin + etoposide and carboplatin + paclitaxel), targeted agents in lung cancer including gefitinib, erlotinib and vandetanib, and the neoadjuvant MVAC regimen for localized bladder cancer. He has received numerous awards in recognition of his contributions to the treatment of lung and genitourinary cancers and has been cited as one of the best cancer doctors by Los Angeles Magazine, Good Housekeeping and each edition of Best Doctors in America since its inception.

Dr. Natale was a tenured faculty member at the University of Michigan, where he also served as associate director of the Comprehensive Cancer Center, and at the University of Southern California, where he served as associate director of medical oncology. Immediately prior to his current position, he served as senior research advisor and director of the National Lung Cancer Research Program for Aptium Oncology, Inc. His current work focuses on targeted therapies in lung cancer and mechanisms of action and resistance.

Dr. Natale holds a B.S. from the University of Michigan and an M.D. from Wayne State University School of Medicine in Detroit, where he also completed his medical residency. He completed a fellowship in hematology/oncology at the Memorial Sloan-Kettering Cancer Center in New York City and a research fellowship at the National Cancer Institute in Bethesda, MD.

Suresh S. Ramalingam, MD
Professor of Hematology/Oncology
Deputy Director
Winship Cancer Institute
Director, Lung Cancer Program
Winship Cancer Institute
Assistant Dean for Cancer Research
Co-Leader, Discovery & Developmental Therapeutics Program
Emory University
Atlanta, GA

Suresh S. Ramalingam, MD top

Dr. Suresh Ramalingam is a key member of the Emory University and Winship Cancer Institute Oncology programs. He is a nationally-recognized leader in cancer research, with specialties in lung cancer, drug discovery and early drug development.

Dr. Ramalingam is certified by the American Board of Medicine and Internal Medicine and Medical oncology and as an active member of the American Society of Clinical Oncology, American Association for Cancer Research and the International Association for the Study of Lung Cancer.

Dr. Ramalingam serves on several international, national and Institutional Committees. He is currently a recipient of peer-reviewed grants from the National Cancer Institute.

Dr. Ramalingam received his MB/BS from Kilpauk Medical College. University of Madras, Madras, India in 1992. He completed his residency in internal medicine at Wayne State University in 1996 where he was also named chief medical resident in department of internal medicine in 1996. He completed his fellowship in hematology and medical oncology at the University of Pittsburgh Cancer Institute 2002.

Dr. Ramalingam’s research currently involves the development of agents that inhibit the mTOR, HDAC, DNA repair and EGFR pathways and in the evaluation methods to individualized therapies for patients. He has conducted several early-phase clinical trials with molecularly targeted agents in the treatment of small cell and Non-small cell lung cancers.

Dr. Ramalingam has authored over 200 scientific publications as the section editor for “Chest Diseases” for the Journal, Cancer. He is also on the editorial boards on the the Journal of Clinical Oncology, Annals of Oncology, and Clinical Lung Cancer.

Dr. Ramalingam is also the recipient of several awards including “James Eckman Award for Excellence in T,” at the Department of Hematology and Medical Oncology of Emory University, and the Distinguished Cancer Scholar Award of the Georgia Cancer Coalition. He is also a recipient of the Career Development Award of the of the American Society of Clinical Oncology (2006-2009).

Gregory J. Riely, MD, PhD
Medical Oncologist
Thoracic Oncology Service
Vice Chair,
Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Gregory J. Riely, MD, PhD top

Dr. Riely is a board-certified medical oncologist who specializes in treating patients with lung cancer and thymic tumors (thymoma and thymic carcinoma). In addition to caring for men and women with these diseases, he works to develop new treatments by designing and conducting clinical trials. His clinical research focuses on the treatment of patients with thymic tumors as well as non-small cell lung cancer with specific mutations (EGFR, KRAS, BRAF, or EML4-ALK mutant non-small cell lung cancer).

Joan H. Schiller, MD
Member, Inova Medical Group
Lung Cancer Group
Hematology/Oncology
Inova Schar Cancer Institute
Falls Church, VA

Joan H. Schiller, MD top

Dr. Joan Schiller is a board certified medical oncologist with over 30 years of clinical experience. She has a special interest in management of lung cancer.Most recently, Dr. Schiller served as Deputy Director of the Simmons Cancer Center and Chief of Hematology/Oncology at the University of Texas Southwestern Medical Center in Dallas, until coming to Inova in 2016.

Dr. Schiller’s research has generated well over 200 publications that she has authored or co-authored, including articles, abstracts, book chapters, books, reviews and invited manuscripts. She has been the principal investigator of numerous clinical trials, and has a major interest in developing better treatment for patients with lung cancer, as well building a robust clinical research program for patients with cancer at Inova.

A native of Chicago, Illinois, Dr. Schiller currently resides in Vienna, Virginia with her husband and 100-pound black lab. In her spare time she likes to visit her grandson in Baltimore.

Mark Socinski, MD
Executive Medical Director,
Florida Hospital Cancer Institute
Orlando, FL

Mark Socinski, MD top

Dr. Socinski is a thoracic oncology expert from the University of Pittsburgh Medical Center (UPMC) Cancer Pavilion. At UPMC, he served as Professor of Medicine and Cardiovascular Surgery; Director of the Lung Cancer Section for the Division of Hematology and Oncology; Co-director of the Lung Cancer Center of Excellence; and Co-director of the Lung Cancer Program. Prior to joining UPMC, Dr. Socinski was Professor of Medicine at the University of North Carolina Department of Medicine.

He is a member of the American Society of Clinical Oncology, the American College of Physicians, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. Dr. Socinski received his medical degree as well as a Master’s of Science in Pathology from the University of Vermont College of Medicine. He completed his residency at Beth Israel Deaconess Medical Center in Boston, and completed fellowships at Dana Farber Cancer Institute in Boston and Harvard Medical School. He is board certified in internal medicine and medical oncology.

Anne S. Tsao, MD
Associate Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Anne S. Tsao, MD top

Dr. Tsao earned her medical degree from the prestigious University of Chicago Pritzker School of Medicine. She completed her internship and residency at Indiana University in Indiana and an additional residency at the University of Texas. Before joining the staff at M.D. Anderson, she also completed a fellowship at the facility. Board certified in both internal medicine and medical oncology, Dr. Tsao specializes in thoracic, head, and neck oncology and serves as director of the Mesothelioma Program at the hospital.

Dr. Tsao and her colleagues at Anderson have penned many articles providing a large amount of information for many professional journals and have been involved in numerous clinical trials involving the treatment of malignant mesothelioma, an aggressive form of cancer that is often diagnosed in advanced stages and difficult to treat.

In articles in publications such as the Journal of Clinical Oncology, Tsao has discussed the impact of novel therapies, the importance of clinical trials, and controversial issues such as the use of extra-pleural pneumonectomy in the treatment of the disease. She has also campaigned for the use of intra-pleural therapies as well as gene therapy and immunotherapy for the treatment of malignant pleural mesothelioma and lectures nationally and internationally on these subjects.

Dr. Tsao has also performed studies involving smoking history and its impact on the prognosis of those with non-small cell lung cancers like mesothelioma. She has also stressed the need for chemo-prevention, the use of natural, synthetic, or biologic chemical agents to suppress cancer in high-risk populations or prevent carcinogenic progression to invasive cancer.

For her work in the field of thoracic and other cancers, Dr. Tsao has been the recipient of numerous awards including an American Society of Clinical Oncology (ASCO) Merit Award, M.D. Anderson Achievement in Research Award, ASCO Young Investigator Award, ASCO Career Development Award, NIH Clinician Scientist K12 Award, and Head and Neck SPORE Career Development Award. Tsao also serves on the Southwest Oncology Steering Committee and is a member of the Scientific Board of the American Radium Society.

Jared Weiss, MD
Assistant Professor
Division of Hematology and Oncology
School of Medicine
Clinical Research
Thoracic Oncology Program
University of North Carolina
Chapel Hill, NC

Jared Weiss, MD top

Clinically, Dr. Weiss is focused on treating patients with lung cancer and head and neck cancers. Dr. Weiss’ research is focused on clinical trials in lung cancer and head/neck cancer. Dr. Weiss serves as section chief of thoracic and head/neck oncology and research POD leader for thoracic oncology. Dr. Weiss serves as associate director for finance of the Clinical Protocol Office. He also serves as the vice president of cancergrace.org, a global resource with the goal of increasing patient education and family information on cancer and is an advocate and board member of the Lung Cancer Initiative of North Carolina.

Dr. Jared Weiss is a medical oncologist in Chapel Hill, North Carolina. He received his medical degree from Yale University School of Medicine and has been in practice between 11-20 years.

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

H. Jack West, MD top

Dr. West received an MPhil in Experimental Biology from Cambridge University on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School, where Dr. West also conducted research as a Howard Hughes Medical Student Fellow. His postdoctoral training included an internship and residency in internal medicine at the Harvard-affiliated Brigham and Women’s Hospital Boston, MA, followed by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/ University of Washington in Seattle, WA. He joined Swedish Cancer Institute in late 2002 as a medical oncologist and lung cancer specialist. He also serves as Medical Director of the Thoracic Oncology Program and has a significant clinical interest as well in genitourinary oncology.

Dr. West has published numerous articles in peer-reviewed literature and has authored several book chapters. He also now serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease, in addition to serving as an author of multiple lung cancer-related sections of Up-To-Date and as a reviewer for more than a dozen professional journals. Dr. West leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a Study Coordinator/Principal Investigator.

Dr. West founded and continues to serve as President of the nonprofit organization Global Resource for Advancing Cancer Education (GRACE), a source of timely, free information for patients and caregivers dealing with cancer that currently receives over 50 thousand visits per month from over 100 countries around the world.

Dr. West is also working to develop telemedicine-based practice patterns to broaden the range of treatment options for cancer patients and serves as the Chair of the Outreach/Education/Telemedicine Working Group for the Cancer Clinical Provider Group as part of the Providence/Swedish Hospital Network. He is also a regular session chair on numerous annual lung cancer an immune and targeted therapy CME symposia such as the Annual Personalized Therapies and Best Clinical Practices Symposia each year in October in San Francisco. He is often a co-chair of satellite educational symposia on lung cancer at the annual meeting of the American Society of Clinical Oncology in Chicago in May and June.

© 2017 Oncology Learning Center, Inc.